GSK acquired worldwide rights to Arrowhead’s hepatitis B treatment, JNJ-3989, with plans to continue its development and potential commercialization. The transaction includes assuming obligations and payments under the original Arrowhead-Janssen deal, with GSK committing to cover up to $1 billion in associated costs. GSK aims to integrate this candidate with its hepatitis B drug, bepirovirsen, aiming for a functional cure. The original agreement also provided Arrowhead with substantial upfront and milestone payments, equity investments, and future royalties.
GSK said on Tuesday that it has acquired the rights to Arrowhead Pharmaceutical’s hepatitis B candidate, which was first in-licensed by J&J’s Janssen Pharmaceuticals in 2018.
Under the terms of the deal, GSK has obtained worldwide exclusive rights to the candidate known as JNJ-3989, originally the ARO-HBV program. The drug is an RNAi-based therapeutic developed as a curative therapy for patients with chronic hepatitis B.
GSK will also take on the obligations of the original license agreement between Arrowhead and Janssen, including any remaining cash that is owed to Arrowhead and any upfront and milestone payments to both Janssen and Arrowhead, which is around $1 billion according to the announcement.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The British biopharma will also continue the candidate’s trials and assume any costs related to any future development and commercialization, while any remaining financial obligations that Janssen may still owe Arrowhead will be GSK’s responsibility.
GSK plans to investigate the JNJ-3989 candidate for use alongside bepirovirsen, its investigational oligonucleotide to treat non-cirrhotic adults with chronic hepatitis B. However, the company did not present any details for any further development efforts.
“We are excited to build on promising results already demonstrated with bepirovirsen to investigate a novel sequential regimen with JNJ-3989. We believe this approach could redefine the treatment paradigm for chronic hepatitis B by helping even more patients achieve a functional cure,” GSK CSO Tony Wood said in a statement.
The original deal in 2018 saw Arrowhead secure a $175 million upfront payment and a $75 million equity investment in the company by Johnson & Johnson Innovation. Arrowhead also got an estimated $1.6 billion in milestone payments for the licensing agreement and around $1.9 billion in costs for three other targets. Arrowhead was also eligible to get royalties in the mid-teens on product sales in the Janssen deal.
GSK and Arrowhead also recently inked a deal. In 2021, GSK paid $120 million upfront to develop and commercialize Arrowhead’s RNAi drug to treat nonalcoholic steatohepatitis.
Janssen has also been culling its partnerships. In May 2023, it ended its collaboration with Bavarian Nordic to develop vaccines for hepatitis B and human papillomavirus.
Source: Biospace